This clinical trial is studying type 2 diabetes in people with overweight or obesity. It compares a new medicine called NNC0487-0111, also known as zenagamtide, with semaglutide, which is already used for weight management and diabetes care. The purpose of the study is to see whether NNC0487-0111 helps lower body weight better than semaglutide and to learn more about its safety.

Both medicines are given as a subcutaneous injection, which means an injection under the skin, once a week. People in the study receive one of several dose plans of NNC0487-0111 or semaglutide, and some study groups receive placebo. The study follows changes in body weight, blood sugar, waist size, blood pressure, and other health measures over time. It also looks at side effects, including low blood sugar, which can happen when blood sugar drops too far.

The study is planned to run for a long period, with treatment and follow-up visits spread across the study time. The medicines are given in a pre-filled pen, and the course of the study is designed to compare how the different treatments work and how safe they are in adults with excess body weight and type 2 diabetes.